DAX22.892 -0,5%ESt505.424 -0,5%Top 10 Crypto11,70 +0,3%Dow41.857 -0,2%Nas17.676 -0,1%Bitcoin77.661 +0,1%Euro1,0818 -0,4%Öl72,15 -0,2%Gold3.019 -0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Tesla A1CX3T RENK RENK73 DEUTZ 630500 NVIDIA 918422 Steyr Motors A40TC4 HENSOLDT HAG000 thyssenkrupp 750000 BYD A0M4W9 Lufthansa 823212 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Commerzbank CBK100 NEL ASA A0B733 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen im Seitwärtsmodus -- DAX verabschiedet sich schwächer ins Wochenende -- Micron Technology übertrifft Erwartungen bei Umsatz und Gewinn -- Douglas, Tesla, DEUTZ, FUCHS, thyssenkrupp im Fokus
Top News
DAX in KW 12: Diese Aktien gehörten zu den Gewinnern und Verlierern DAX in KW 12: Diese Aktien gehörten zu den Gewinnern und Verlierern
Schwacher Wochentag in New York: S&P 500 zeigt sich am Freitagmittag leichter Schwacher Wochentag in New York: S&P 500 zeigt sich am Freitagmittag leichter
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Almirall Aktie

NeuKaufenVerkaufen
Almirall Aktien-Sparplan
10,22 EUR ±0,00 EUR ±0,00 %
STU
10,27 EUR -0,06 EUR -0,58 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.2,22 Mrd. EUR

KGV171,56
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0MU8Y

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINES0157097017

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLBTSF

Almirall Aktien News

DatumMeistgelesen
BusinesswireAlmirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
BusinesswireAlmirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
BusinesswireNew Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
Wer­bungAlmirall-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireAlmirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
BusinesswireNICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe Atopic Dermatitis in the NHS England in Eligible Adolescents and Adults
BusinesswireAlmirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
BusinesswireAlmirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year1
BusinesswireAlmirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
BusinesswireAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BusinesswireAlmirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BusinesswireAlmirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
BusinesswireAlmirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
BusinesswireAlmirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
BusinesswireAlmirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
BusinesswireAlmirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
BusinesswireAlmirall’s Nine-month 2023 Results:
BusinesswireAlmirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
BusinesswireAlmirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
BusinesswireAlmirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis
BusinesswireEBGLYSS® (Lebrikizumab) erhält positive CHMP-Stellungnahme für mittelschwere bis schwere atopische Dermatitis
BusinesswireEBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
BusinesswireAlmirall’s H1 2023 Results: Almirall Achieves Net Sales Growth of 7% to €466.1MM, Driven by Strong Growth in European Dermatology Business
BusinesswireAlmirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis
BusinesswireAlmirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
BusinesswireAlmirall announces the pricing and closing of its €200mm non pre-emptive share capital increase
BusinesswireAlmirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
finanzen.netAlmirall gab Ergebnis zum abgelaufenen Quartal bekannt
BusinesswireAlmirall’s First Quarter 2023 Results
BusinesswireAlmirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
BusinesswireAlmirall, The First to Assess Wellbeing in a Dermatology Clinical Study
BusinesswireAlmirall’s Full-Year 2022 Results
BusinesswireAlmirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BusinesswireAlmirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
BusinesswireAlmirall’s Nine-month 2022 Results
PR NewswireAlmirall opens a new subsidiary for the Czech Republic and Slovakia
PR NewswireAlmirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis
PR NewswireAlmirall: Tildrakizumab is the first and only IL-23p19 inhibitor to demonstrate meaningful sleep improvement in people living with psoriasis
PR NewswireAlmirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials
PR NewswireAlmirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
PR NewswireAlmirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
Wer­bung

Almirall News

Almirall News: auf dieser Seite finden Sie alle Almirall News und Nachrichten zur Almirall Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Almirall News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Almirall News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.